Don’t miss the latest developments in business and finance.

TB Alliance grants Lupin non-exclusive license to manufacture anti-TB drug

Image
Capital Market
Last Updated : Sep 06 2021 | 11:04 AM IST
Non-profit drug developer, TB Alliance has granted global pharma major Lupin, a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug BPaL regimen. Lupin intends to commercialize the antituberculosis (TB) medicine in approximately 140 countries and territories, including many of the highest TB burden countries around the world.

Powered by Capital Market - Live News

Also Read

First Published: Sep 06 2021 | 10:37 AM IST

Next Story